Thus, elevated ChREBP could be a possible risk factor in human hepatocarcinogenesis, especially related to diabetes and NAFLD, and could also be a potential target in anti-tumoral therapy. Here, MLXIPL is linked to metabolic dysfunction-associated steatotic liver disease.